Page 5 - Ingmar Hoerr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lagging behind in COVID-19 vaccine race, CureVac bets on a easier to store, mass produce jab CureVac's product also requires a far lower dosage of just 12 micrograms, compared to 30 micrograms for BioNTech and 100 for Moderna, allowing for faster mass manufacturing. Agence France-Presse December 17, 2020 11:44:18 IST CureVac took a major leap forward on Monday when it announced the start of final phase three trials for its Covid-19 vaccine candidate, involving more than ...

Updated Dec 17, 2020 | 10:16 IST CureVac CEO Franz-Werner Haas readily admits his German biotech firm is "a bit behind" in the Covid-19 vaccine race, despite using the same cutting-edge technology as rivals Moderna and Pfizer/BioNTech. CureVac 'bit behind' COVID-19 vaccine race, says company CEO | Photo Credit: Pixabay  CureVac CEO Franz-Werner Haas readily admits his German biotech firm is "a bit behind" in the Covid-19 vaccine race, despite using the same cutting-edge technology as rivals Moderna and Pfizer/BioNTech. But with a jab that is easier to store and mass...

Pictures by Thomas Kienzle. Video via Zoom by Michelle Fitzpatrick CureVac CEO Franz-Werner Haas readily admits his German biotech firm is "a bit behind" in the Covid-19 vaccine race, despite using the same cutting-edge technology as rivals Moderna and Pfizer/BioNTech. But with a jab that is easier to store and mass produce, Haas is confident CureVac has found a winning formula -- and that more medical breakthroughs are just around the corner. "There is definitely a race, but a race against the virus, against time," Haas, 50, told AFP, downplaying the competition between vaccine makers. CureV...

Behind in vaccine race, CureVac bets on ‘easier’ jab AFP President Vladimir Putin said Russia had become the first country to register a coronavirus vaccine, though the announcement was met with caution from scientists and the World Health Organization who said it still needed a rigorous safety review. Russian Direct Investment Fund/AFP/File/Handout CureVac took a major leap forward on Monday when it...

Behind in vaccine race, CureVac bets on ‘easier’ jab 345 Haas readily admits his German biotech firm is “a bit behind” in the Covid-19 vaccine race, despite using the same cutting-edge technology as rivals Moderna and Pfizer/BioNTech. But with a jab that is easier to store and mass produce, Haas is confident CureVac has found a winning formula — and that more medical breakthroughs are just around the corner. “There is definitely a race, but a race against the virus, against time,” Haas, 50, told AFP, downplaying the competition between vaccine makers. start of final phase three ...